Clinical trials: Hematological Patients
Hematological Malignancies
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
The primary objectives of this study are: To confirm the safety and tolerability of magrolimab monotherapy in a relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) population, and of…
- Trial name
- NCT03248479
- Testing
- Magrolimab, Azacitidine
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 258 people
- Sponsor
- Gilead Sciences
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
- Conditions
- B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma
- Trial name
- NCT00446342
- Testing
- SNS-032 Injection
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sunesis Pharmaceuticals
Cytopenia
Low Bacterial Diet in Patients With Cytopenia
The purpose of this prospective, randomized study was to determine the efficacy of low bacterial diet, in comparison to normal hospital diet, with gut colonization by aerobic Gram negative rods and yeasts as primary endpoint.
- Trial name
- NCT00367588
- Testing
- Low bacterial diet
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Maastricht University Medical Center
Cancer, Caregivers
Psychoeducation for AlloHCT Caregivers
Background: Caregivers of patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for hematological malignancies face significant challenges that can impact their well-being.
- Conditions
- Cancer, Caregivers, Stem Cell Transplant, Psychoeduction
- Trial name
- NCT07116018
- Testing
- Psychoeducation
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- University Health Network, Toronto
Hemato-oncologic Patients, Colonization
Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae
The goals of this observational study are to identify risk factors for ESBL-producing Enterobacterales and carbapenemase-producing Enterobacterales (CPE) colonization in oncohematological patients with severe neutropenia, and to…
- Conditions
- Hemato-oncologic Patients, Colonization, Neutropenia, Enterobacteria Non Susceptible to Carbapenem Carrier
- Trial name
- SCREEN-IN (NCT07396571)
- Where
- 15 sites in Spain
- Volunteers
- 535 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Myelodysplastic Syndromes
A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.
This single arm study will evaluate the efficacy and safety of a combination of NeoRecormon, CellCept and prednisone in patients with low or moderate risk myelodysplastic syndromes (MDS).
- Trial name
- NCT00551291
- Testing
- Mycophenolate mofetil, Prednisone, Erythropoietin Beta
- Where
- 8 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
This study will determine the safety and effectiveness of an experimental vaccine in controlling the abnormal growth of cells in patients with myelodysplastic syndrome (MDS, also known as myelodysplasia), acute myeloid leukemia…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
- Trial name
- NCT00433745
- Testing
- WT1 Peptide Vaccine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematological Malignancy, Leukemia
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
The purpose of this study is to determine the safety and anti-tumor effects of an experimental immunotherapy drug, called AlloStim, which is intentionally mis-matched immune cells which are designed to elicit the same anti-tumor…
- Conditions
- Hematological Malignancy, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00558675
- Testing
- AlloStim
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Mirror Biologics, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00522990
- Testing
- AT9283
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
MDS/AML with MRD and impending relapse after allogeneic stem cell transplantation and/or conventional chemotherapy
- Conditions
- Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Minimal Residual Disease
- Trial name
- NCT04712942
- Testing
- Pevonedistat, Azacitidine
- Where
- 14 sites in Germany
- Volunteers
- 14 people
- Sponsor
- University of Leipzig
Hematological Diseases, Hematological Malignancies
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.
- Conditions
- Hematological Diseases, Hematological Malignancies, Blood Diseases, Malignant Lymphoma
- Trial name
- Bismuth-PBH (NCT00892502)
- Testing
- Bismuth tablets
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Copenhagen University Hospital at Herlev
Hematological Cancers, Frailty
Improving Quality of Life in Frail, Older Patients with Hematological Cancer Through Geriatric Assessment and Treatment - a Pilot Study
Purpose of the Study This study aims to assess the feasibility of conducting outpatient geriatric health assessment (comprehensive geriatric assessment - CGA) alongside initiation of hematological cancer treatment in frail older…
- Conditions
- Hematological Cancers, Frailty, ELDERLY PEOPLE
- Trial name
- IMPROVE pilot (NCT06689332)
- Testing
- Comprehensive Geriatric Assessment
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- Odense University Hospital
Invasive Fungal Infection
Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection
Invasive fungal infections (IFI) remain the major cause of death among neutropenic patients receiving chemotherapy for leukemia, or submitted to stem cell transplantation.
- Trial name
- NCT01198236
- Testing
- Itraconazole
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang University
GVHD, Chronic, Hematological Malignancy
Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT
A two sited feasibility study to test the feasibility of systematic symptom identification with disease specific and clinically developed PROM (Lee Symptom Scale) longitudinally with a 12 month follow up in outpatient care in…
- Trial name
- SIMPly-CARE (NCT04884204)
- Testing
- Lee Symptom Scala
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Waldenstrom Macroglobulinaemia, Multiple Myeloma
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
- Trial name
- BLOOD-dose (NCT07474961)
- Testing
- teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib)
- Where
- 5 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Anne Louise Tølbøll Sørensen
Advanced Solid Tumor, Hematological Malignancy
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
- Trial name
- NCT06225856
- Testing
- YY201
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Yuyao Biotech Co., Ltd.
Hematological Malignancies, Bacteremia
Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients
Patients with a hematological malignancy who are undergoing intensive chemotherapy need a central venous catheter (CVC)during their treatment. CVCs are locked with heparin when they are not used.
- Conditions
- Hematological Malignancies, Bacteremia, Thrombosis
- Trial name
- NCT01820962
- Testing
- heparin, concentrated citrate
- Where
- 2 sites in Netherlands
- Volunteers
- 212 people
- Sponsor
- Maastricht University Medical Center
Platelet Transfusion, Hematological Malignancy
Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematological Malignancies (R-PLQ)
Limited data is available for end of life care in hematologic malignancies, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its…
- Conditions
- Platelet Transfusion, Hematological Malignancy, Palliative Care
- Trial name
- R-PLQ (NCT03806712)
- Testing
- multi method questionary (developped by De Rosa, in 1995 and 2014)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hematological Malignancy, Prehabilitation
Investigation of the Effects of Prehabilitation Education Delivered Through a Mobile Compatible Website on Quality of Life and Symptoms in Patients Undergoing Hematopoietic Stem Cell Transplantation
Aim of the Study: The aim of this study is to examine the effect of prehabilitation education delivered via a mobile-compatible website on the quality of life and symptom evaluation of patients undergoing hematopoietic stem cell…
- Conditions
- Hematological Malignancy, Prehabilitation, Patient Education
- Trial name
- NCT07066592
- Testing
- Prehabilitation education provided via mobile compatible website
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Saglik Bilimleri Universitesi
Myelodysplastic Syndromes, Leukemia Myeloid Acute
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies
The elderly comprise the most prevalent population in oncology practice. The available evidence suggests that old patients are undertreated patients, mainly because of their advanced age, regardless of whether they are highly…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leuklemia, Lymphocytic, Chronic
- Trial name
- GAH (NCT02164071)
- Testing
- Geriatric Assessment of Health Status Scale administration
- Where
- 22 sites in Spain
- Volunteers
- 363 people
- Sponsor
- Celgene